NCT05668897已完成1 期
A Randomized, Double-blind, Placebo-controlled Single-dose and Multiple-dose Ascending Phase Ia Clinical Trials in Healthy Subjects To Evaluate the Safety, Tolerability and Pharmacokinetics of GST-HG171 Tablets
Fujian Akeylink Biotechnology Co., Ltd.1 个研究点 分布在 1 个国家目标入组 78 人开始时间: 2022年10月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 78
- 试验地点
- 1
- 主要终点
- safety and tolerability
研究概览
简要总结
To Evaluate the Safety, Tolerability and Pharmacokinetics on GST-HG171 Tablets in Randomized, Double-blind, Placebo-controlled Single-dose and Multiple-dose ascending Phase Ia Clinical Trials in Healthy Subjects
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Sign the informed consent before the trial and fully understand the content, process and possible adverse reactions of the trial;
- •Ability to complete research in accordance with test plan requirements;
- •Subjects (including partners) are willing to take effective pregnancy avoidance measures within 6 months after screening to the last study drug administration;
- •Male and female healthy subjects aged 18 to 50 years (including 18 and 50 years old);
- •Male subjects weigh no less than 50 kg, and female subjects weigh no less than 45 kg. Body mass index (BMI) = body weight (kg) / height 2 (m2), body mass index is in the range of 18 ~ 28 kg / m2 (including critical value);
- •Physical examination, normal or abnormal vital signs have no clinical significance.
排除标准
- •Allergies (multiple drugs and food allergies);
- •Those who smoked more than 5 cigarettes per day in the 3 months before the trial;
- •Have a history of drug abuse and / or alcoholism (drink 14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine);
- •Blood donation or massive blood loss (> 400 mL) within three months before screening;
- •Have a history of dysphagia or any gastrointestinal disease that affects drug absorption, including a history of frequent nausea or vomiting caused by any cause;
- •Have any disease that increases the risk of bleeding, such as hemorrhoids, acute gastritis, or gastric and duodenal ulcers;
- •Have taken the study drug or participated in the drug clinical trial within three months before taking the study drug;
- •Have Intended to take any drug that changes the activity of drug metabolizing enzyme 28 days before screening or during the study, including strong inhibitors and inducers that affect the metabolizing enzyme;
- •Took any prescription drugs or herbs within 14 days before screening, or took over-the-counter drugs or any vitamin products within 7 days before screening;
- •Vaccinated within 14 days before screening or planned to be vaccinated during the study;
- •Those who have taken special diets (including dragon fruit, mango, grapefruit, etc.) or have vigorous exercise or other factors affecting drug absorption, distribution, metabolism, excretion, etc. within 2 weeks before screening;
- •Those who cannot tolerate high fat (about 50% of the total calories) and high calorie (about 800~1000 calories) standard meals (only applies to subjects participating in the food effect study);
- •Abnormal ECG has clinical significance;
- •Female subjects were breastfeeding or had a positive serum pregnancy result during the screening period or during the study;
- •Clinical laboratory examinations are abnormal and clinically significant, or find the following diseases with clinical significance (including but not limited to gastrointestinal tract, kidney, liver, nerve, blood, endocrine, tumor, lung, Immune, mental or cardiovascular disease) within 6 months before screening;
- •Positive screening for viral hepatitis (including hepatitis B and C), AIDS antigen / antibody, and Treponema pallidum antibody;
- •Acute disease or concomitant medication occurs from the screening stage to before study medication;
- •Ingested chocolate, any caffeinated or xanthine-rich food or drink 24 hours before taking the study drug;
- •People who have a positive urine drug screen or have a history of drug abuse or have used drugs within the past five years;
- •The investigator believes that there are other subjects who are not suitable for participating in this trial.
研究组 & 干预措施
Single-dose ascending group
Experimental
SAD study cotains at least 4 cohorts at dosage of 150mg, 300mg, 600mg and 900mg. Each cohort enrolls 6 subjects receive study drug.
干预措施: GST-HG171 (Drug)
SAD placebo comparator group
Placebo Comparator
SAD study cotains at least 4 cohorts at dosage of 150mg, 300mg, 600mg and 900mg. Each cohort enrolls 2 subjects receive placebo.
干预措施: placebo of GST-HG171 (Drug)
Multi-dose ascending group
Experimental
MAD study cotains 1-3 cohorts which were evaluated in SAD study to be tolerated . Each cohort enrolls 6 subjects receive study drug.
干预措施: GST-HG171 (Drug)
MAD placebo comparator group
Placebo Comparator
MAD study cotains 1-3 cohorts which were evaluated in SAD study to be tolerated . Each cohort enrolls 2 subjects receive placebo.
干预措施: placebo of GST-HG171 (Drug)
Food effect study
Experimental
FE study cotains at least 1 cohort which were evaluated in SAD study to be tolerated . Each cohort enrolls 12 subjects receive study drug on fast or fed condition.
干预措施: GST-HG171 (Drug)
结局指标
主要结局
safety and tolerability
时间窗: SAD up to Day 5 and MAD up to Day 9
Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v5.0
次要结局
- Area Under Curve (AUC)(Measured on -0.5, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96hours in single-dosing. In the multiple dose group, measured on -0.5, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12hours on Day1, more details in protocol.)
- Cl/F(Measured on -0.5, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96hours in single-dosing. In the multiple dose group, measured on -0.5, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12hours on Day1, more details in protocol.)
- Fe(0~120h)(Measured on -0.5, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96hours in single-dosing. In the multiple dose group, measured on -0.5, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12hours on Day1, more details in protocol.)
- Ae(0~120h)(Measured on -0.5, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96hours in single-dosing. In the multiple dose group, measured on -0.5, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12hours on Day1, more details in protocol.)
- Peak Plasma Concentration (Cmax)(Measured on -0.5, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96hours in single-dosing. In the multiple dose group, measured on -0.5, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12hours on Day1, more details in protocol.)
- T1/2(Measured on -0.5, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96hours in single-dosing. In the multiple dose group, measured on -0.5, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12hours on Day1, more details in protocol.)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Pharmacokinetics and Safety of GST-HG171 Tablets in Subjects With Impaired and Normal Liver FunctionCOVID-19 PneumoniaNCT06106113Fujian Akeylink Biotechnology Co., Ltd.24
招募中
不适用
Pharmacokinetics and Safety of GST-HG171 Tablets in Subjects With Impaired and Normal Renal FunctionCOVID-19 PneumoniaNCT06106126Fujian Akeylink Biotechnology Co., Ltd.32
Unknown
1 期
Study on the Tolerance and Pharmacokinetics of GST-HG141 TabletsHepatitis BNCT04386915Fujian Cosunter Pharmaceutical Co. Ltd104
Unknown
1 期
Safety, Tolerability and Pharmacokinetic Characteristics Evaluation of GST-HG131 TabletsHepatitis BNCT04499443Fujian Cosunter Pharmaceutical Co. Ltd124
已完成
1 期
Study on the Tolerability, Pharmacodynamics and Pharmacokinetics of GST-HG141 TabletsHepatitis BNCT04868981Fujian Cosunter Pharmaceutical Co. Ltd30